Multiple Sclerosis Community Celebrates World MS Day

World MS Day is celebrated onĀ May 27 as a day dedicated to thoseĀ who suffer fromĀ multiple sclerosis (MS). In order to mark the occasion, organizations, companies, advocates, and communities are hosting events throughout the worldĀ to share inspiring stories, raise awareness about the disease and campaign to support both patients…

AUBAGIO Included in Prince Edward Island Pharmacare

Canadian province Prince Edward Island (PEI) has approved the inclusion of Aubagio (teriflunomide) 14 mg in the PEI Pharmacare’s provincial drug formulary. This means that the drug developed and commercialized byĀ Genzyme is now financially supported by the state as aĀ first-line oral tablet to treat patients who…

Progressive MS Challenges to Be Dicussed at CMSC Meeting

The needs of patients who suffer from progressive multiple sclerosis (MS) willĀ be addressed in a presentation hosted byĀ Alan Thompson, MD, FRCP, from the University College London (UCL) duringĀ theĀ Donald Paty Memorial Lecture. The Lecture will take place during the Consortium of Multiple Sclerosis Centers (CMSC) 29th Annual…

11-Year Follow-up of Bayer’s BENEFIT Interferon-beta1b Treatment Reveals Positive Results For MS Patients

Results from the BENEFIT11 trial indicate thatĀ early treatment with IFNB-1b leads to improvements inĀ cognition and fatigue in the long-term, as well as sustained employment and favorable magnetic resonance imaging (MRI) outcomes, measured at the 11-year mark. Supported byĀ Bayer HealthCare Pharmaceuticals, the study, titled “Long-term Impact of Early MS Treatment with…

Genzyme Announces New Research Collaboration With Ablynx for Innovative Multiple Sclerosis Therapeutic Project

This week, Belgian-based biopharmaceutical company Ablynx announced they have entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate the use of Nanobodies as part of a targeted therapeutic strategy for multiple sclerosis (MS). Ā The research will utilize Genzymeā€™s early-stage MS research programs involving neuroprotection…

MSAA Organizes Make a Splash Fundraising Event for Memorial Day

The Multiple Sclerosis Association of America (MSAA) is organizing a national fundraising campaignĀ just inĀ time for summer. TheĀ Swim for MSĀ event willĀ help the association fund activities and support the multiple sclerosis (MS)Ā community with crucialĀ services to help improve the lives of the 400,000 people in the United…

Gut Bacteria: Key to MS?

There has been a great deal of recent interest in the connection between nervous system function and the complex bacteria that are found in the gastrointestinal system, known as the gut microbiome. Some scientists believe that differences in the type of bacteria found in the gut mayĀ underlie neurological disease. In…

Amarantus Releases Preliminary Data From Blood-Based MS Diagnostic

Amarantus BioScienceĀ has released preliminary data from a blood test for multiple sclerosis (MS)Ā called theĀ MSPrecise diagnostic. The company believes that the test could lead to more accurate diagnoses of MSĀ early in the disease’s progression. MSPrecise is a DNA sequencing test designed to identify specific DNA mutations that are associated with the…

Problem Drinking in MS Associated with Anxiety and Family History

Multiple sclerosis (MS) presents many life-altering challenges, but mostĀ patients naturallyĀ focus most often on the physical challenges associated with the condition: problems with movement, sensation and vision that occur as part of disease progression. Unfortunately, depression and suicidal thoughts are common as well. New research suggests that thereĀ could be a relationship…

Student Changes Life Plans to Help Others with MS

Just like any student, Stephanie Butler was excited to start working, in her case as a nurse, when she beganĀ experiencing numbness in herĀ limbs and lost sensation below the waist. It was the first time the student nurse was goingĀ to administer anesthesia to a patient, three years ago, when after a…

MediciNova Completes Enrollment for Phase 2b Study of Experimental Progressive Multiple Sclerosis Treatment

MediciNova, Inc., a publicly-traded biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the National Institute of Neurological Disorders and Stroke (NINDS) notified the company of full enrollment of theirĀ ongoing clinical study evaluating ibudilastĀ (MN-166) for the treatment of progressive…

Innate Immunotherapeutics Joins MS Consortium

US-basedĀ Multiple Sclerosis Outcome Assessments Consortium (MSOAC) has invited New Zealand-basedĀ Innate Immunotherapeutics Limited to join their efforts to developĀ clinical outcome assessment tools to be used in clinical research on multiple sclerosis (MS). The tool being developedĀ is expected to includeĀ a series of tests while improving, accelerating and evaluating…

Myelin Repair Foundation and NIH to Study Guanabenz for MS

The Myelin Repair Foundation (MRF) and National Institutes of HealthĀ (NIH)Ā will initiateĀ a clinical trial of guanabenz in people with multiple sclerosis (MS). Guanabenz is FDA-approved for high blood pressure, but it may also prevent myelin loss. The drug could be the first for MS to protect myelin from…